Anti-Human/Rat HER2 (neu) Antibody (7.16.4) 

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is an anti-human and anti-rat HER2 IgG2a monoclonal antibody. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) reduces tumor cell proliferation by inhibiting the HER2 signaling pathway. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can activate CD8⁺ T cells. Anti-Human/Rat HER2 (neu) Antibody (7.16.4) can be used for research on cancer such as breast cancer^[1][2].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human/Rat

HER2 (neu)

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (10 mg/kg, i.p., twice a week, for 21 days) significantly delays tumor growth combined with Pyrotinib (HY-104065) in female BALB/c mice bearing TUBO tumors^[1].
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (100 μg, i.p., once daily, from day 13 to day 17) delays tumor growth in female BALB/c mice bearing TUBO tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

24337  [NCBI]

AAH61863

in vivo HER2/neu inhibition; in vitro HER2/neu inhibition; Immunoprecipitation; Immunofluorescenc

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Human/Rat HER2 (neu) Antibody (7.16.4)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1×10⁶ MCF-7 cells labeling Anti-Human/Rat HER2 (neu) Antibody (7.16.4) (HY-P990238, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG2a kappa Isotype Control (HY-P99978, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Liu S, et al. Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. EBioMedicine. 2024 Nov;109:105379.  [Content Brief]

  [2]. Xu M, Du X, Liu M, Li S, Li X, Fu YX, Wang S. The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 2012 Jun;3(6):441-9.  [Content Brief]